| RARα (retinoic acid receptor alpha), a founding member of the nuclear receptor superfamily alongside RARβ/γ and RXR isoforms, functions primarily as an RXR heterodimeric transcription factor that senses all-trans retinoic acid (ATRA) to regulate gene expression critical for embryonic patterning, hematopoiesis, and epithelial differentiation. Its modular architecture includes a DNA-binding domain with two zinc fingers for retinoic acid response element (RARE) recognition and a ligand-binding domain that undergoes conformational rearrangement upon ATRA binding to exchange corepressors (NCoR/HDAC) for coactivators (SRC/p300). In the absence of ligand, RARα-RXR silences target genes like HOX clusters and Cdx1 through HDAC-mediated chromatin compaction, whereas ATRA binding induces helix 12 repositioning, CBP recruitment, and H3K14 acetylation to activate transcription while promoting receptor phosphorylation by JNK and proteasomal turnover for signal termination. This dynamic switches integrate with Wnt/β-catenin antagonism, where RARα represses LEF/TCF targets, and TGF-β/Smad pathways via direct heterodimerization, fine-tuning mesenchymal-to-epithelial transitions during development and curtailing aberrant proliferation in keratinocytes. RARα governs granulopoiesis, limb bud outgrowth, and skin barrier formation, positioning it as a key effector for researchers modeling retinoid pharmacodynamics in APL patient-derived xenografts or dissecting squamous differentiation via ChIP-seq in organotypic cultures. The t(15;17) PML-RARα fusion in acute promyelocytic leukemia constitutively recruits corepressors to RAREs, blocking differentiation until supraphysiologic ATRA doses relieve repression, unveiling its therapeutic vulnerability. |
Lane 1: T47D, Lane 2: MCF7, Lane 3: HepG2
